With the potential for a hard-no-deal Brexit becoming closer to reality with each passing day, the question of what this means for healthcare and pharma is ever more prominent. To gain some ...

Pharma can use Brexit to ensure it remains the jewel in the crown of UKplc. But there are real problems to address, not least the fact that the NHS is greatly underfunded, with even well ...

GlobalData’s report focuses on the likely impact of Brexit on healthcare, including the pharma sector, and evolving industry views on it. Brexit will have a far reaching impact on research and ...

India Business News: The Brexit impact on pharma industry will be around Rs 400-500 crore, with companies facing issues in regulatory and approval process going forward.

The road ahead… Brexit impact on Indian pharma is going to be minimal, as the UK and the EU account for less than 13 per cent of the overall Indian pharma revenues.

In January, the prime minister, Theresa May, warned the EU that “no deal for Britain is better than a bad deal” when it comes to Brexit. Although her government is now edging away from that position, ...

Rachel Reeves says uncertainty about Brexit is "very concerning" for the UK pharmaceutical industry.

The impact of Brexit on the pharmaceutical industry has yet to be determined, but some fear that Brexit will cause the UK to lag behind in the biosimilar sphere in particular.

GEN subsequently asked a number of biotech scientists and CEOs, both within and without the U.K. and the EU, for their opinion on the potential impact of Brexit on pharma, life science, and ...

Brexit and the Healthcare Industry - Implications for Pharma, Q3 2018: Key Factors to Impact the Post-Brexit UK Healthcare Industry Providing Respondent Mix by Region and Seniority Level ...

Sameer Walia, Managing Director, The Smart Cube examines the potential implications of Brexit on the overall pharma industry in India In early 2016, multiple reports from different research houses ...

Brexit may affect the cost of medicines and hit UK pharmaceutical investment, a Commons committee head has warned. Rachel Reeves, who chairs the Business, Energy and Industrial Strategy (BEIS) ...